Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
Journal: The New England journal of medicine
Published: September 15, 2021
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults.
Journal: Vaccines
Published: October 11, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
Journal: JCI insight
Published: February 10, 2020
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: October 07, 2019
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 25, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Journal: The Lancet. Infectious diseases
Published: February 13, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
Journal: The Journal of infectious diseases
Published: December 07, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 05, 2018
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 29, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.
Journal: Molecular therapy oncolytics
Published: September 02, 2016
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 11, 2016
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Journal: Lancet (London, England)
Published: September 21, 2015
Last Updated: 09/26/2026